Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2006-11-08
2009-11-03
Ouspenski, Ilia (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S134100, C530S387100, C530S387300
Reexamination Certificate
active
07611702
ABSTRACT:
The present invention provides methods for treating adverse events related to immunotherapy. More specifically, the present invention provides methods for treating the enterocolitis associated with anti-CTLA-4 antibody immunotherapy.
REFERENCES:
patent: 5656272 (1997-08-01), Le et al.
patent: 5811097 (1998-09-01), Allison et al.
patent: 5855887 (1999-01-01), Allison et al.
patent: 6207156 (2001-03-01), Kuchroo et al.
patent: 6682736 (2004-01-01), Hanson et al.
patent: 6984720 (2006-01-01), Korman et al.
patent: 2002/0086014 (2002-07-01), Korman et al.
patent: 2004/0241169 (2004-12-01), Lowy et al.
patent: 2005/0201994 (2005-09-01), Korman et al.
patent: WO9842752 (1998-10-01), None
patent: WO0037504 (2000-06-01), None
patent: WO0114424 (2001-03-01), None
Huang Z., Pharmacology and Therapeutics, 2000, 86: 201-215.
Phan et al., PNAS, 2003, 100: 8372-8377.
Van Assche et al., Curr. Opin. Gastroenterol., Jul. 2005, 21: 443-447.
Gray et al., Clinical Science, 2006, 111: 93-106 (privided by Applicant).
Hochberg et al., Semin. Arthritis Rheum, 2005, 34: 819-836 (provided by Applicant).
Spencer et al., Gastroenterology, 2002, 122: 94-109 (provided by Applicant).
Brown et al., 2002, Arthritis and Rheumatism, 46: 3151-3158 (provided by Applicant).
Balzano et al., “CTLA-4 and CD28: similar proteins, neighbouring genes,” Int J Cancer Suppl. 1992;7:28-32.
Hurwitz et al., “CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma,” Proc Natl Acad Sci U S A. Aug. 18, 1998;95(17):10067-71.
Mokyr et al., “Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice,” Cancer Res. Dec 1, 1998;58(23):5301-4.
Murata et al., “Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28, and their mRNA in inflammatory myopathies,” Am J Pathol. Aug. 1999;155(2):453-60.
Camacho et al. (2004). J. Clin. Oncology. 22(145):abstract No. 2505, “Phase 1 clinical trial of anti-CTLA4 human monoclonal antibody CP-675,206 in patients (pts) with advanced solid malignancies”.
Fischkoff Steven
Lowy Israel
Yang James Chung-Yin
Yellin Michael
Baker & Botts L.L.P.
Medarex Inc.
Ouspenski Ilia
LandOfFree
TNF-alpha blocker treatment for enterocolitis associated... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with TNF-alpha blocker treatment for enterocolitis associated..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and TNF-alpha blocker treatment for enterocolitis associated... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4096735